-
公开(公告)号：US09469854B2
公开(公告)日：2016-10-18
申请号：US14873275
申请日：2015-10-02
Applicant: Academia Sinica
Inventor： Shui-Tein Chen , Ting-Fang Lo , Wei-Chung Tsai
IPC: A61K48/00 , C07H21/04 , C07H21/02 , C12N15/113 , A61K31/4375 , A61K31/7105
CPC classification number: C12N15/1137 , A61K31/4375 , A61K31/7105 , C12N15/113 , C12N2310/141 , C12N2320/30 , C12N2320/32
Abstract: The present invention relates to a pharmaceutical composition for treating liver diseases, comprising a miRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). The miRNA mimic of the present invention can be used to treat liver diseases through regulating the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B), acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB), diglyceride acyltransferase 2 (DGAT2), and so on. In addition, the present invention also relates to a method for reducing the expression of the above-mentioned enzymes.
Abstract translation: 本发明涉及用于治疗肝脏疾病的药物组合物，其包含含有hsa-miR-21-3p（SEQ ID No：35）的单链RNA分子的miRNA模拟物。 本发明的miRNA模拟物可用于通过调节甲硫氨酸腺苷转移酶2A和2B（MAT2A和MAT2B），乙酰辅酶A羧化酶1和2（ACACA和ACACB），甘油二酯酰基转移酶2（DGAT2）的表达来治疗肝脏疾病。 等等。 此外，本发明还涉及降低上述酶表达的方法。
-
公开(公告)号：US09434934B2
公开(公告)日：2016-09-06
申请号：US14903194
申请日：2014-07-17
Applicant: Academia Sinica
Inventor： Meng-Chiao Ho , Shih-Hsiung Wu , Wan-Ling Wu
CPC classification number: C12N9/52 , C07K14/39 , C07K2319/00 , C07K2319/02 , C07K2319/21 , C07K2319/22 , C07K2319/50 , C12N15/52 , C12P21/06 , C12Y304/21
Abstract: A fusion gene encoding M. taiwanensis WR-220 keratinase is disclosed. The fusion comprises: (a) a first DNA sequence encoding a protein secretion signal peptide, located at the N-terminus of the fusion gene; (b) a second DNA sequence encoding an inhibitory domain of M. taiwanensis WR-220 keratinase, linked in translation frame with the first DNA sequence; and (c) a third DNA sequence encoding a catalytic domain of M. taiwanensis WR-220 keratinase, linked in translation frame with the second DNA sequence, wherein the fusion gene is a non-naturally occurring chimeric DNA. Also disclosed are a method for preparation of the catalytic domain of M. taiwanensis WR-220 keratinase, and use of the M. taiwanensis WR-220 keratinase.
Abstract translation: 公开了一种编码台湾华ensis WR-220角蛋白酶的融合基因。 融合物包含：（a）编码位于融合基因N末端的蛋白质分泌信号肽的第一DNA序列; （b）编码与第一DNA序列连接的翻译框架的台湾华ensis WR-220角蛋白酶的抑制结构域的第二DNA序列; 和（c）编码与第二DNA序列连接的翻译框架的台湾华南WR-220角蛋白酶的催化结构域的第三DNA序列，其中融合基因是非天然存在的嵌合DNA。 还公开了一种制备M. taiwanensis WR-220角蛋白酶的催化结构域的方法，并使用了台湾华氏WR-220角蛋白酶。
-
公开(公告)号：US09427466B2
公开(公告)日：2016-08-30
申请号：US14808940
申请日：2015-07-24
Applicant: Academia Sinica
Inventor： Olga K. Kosheleva , Peter Lai , Nelson G. Chen , Michael Hsiao , Chung-Hsuan Chen
CPC classification number: A61K41/0033 , A61K41/0028 , A61K47/6923 , A61N7/00 , A61N7/02 , Y10S977/773 , Y10S977/911
Abstract: Methods for reducing the growth of breast cancer cells in a subject by exposing the cells to nanoparticles, and irradiating with a focused, low to medium power ultrasound. The nanoparticles can be gold or magnetic nanoparticles. The nanoparticles can have a cancer drug attached, such as an antibody-based cancer drug.
Abstract translation: 通过将细胞暴露于纳米颗粒并用聚焦的低至中等功率超声照射来减少受试者的乳腺癌细胞生长的方法。 纳米颗粒可以是金或磁性纳米颗粒。 纳米颗粒可以具有连接的癌症药物，例如基于抗体的癌症药物。
-
354.发明授权Imaging of biological structures by changing the position or distance of the structures between a source and a detector 有权通过改变源和检测器之间的结构的位置或距离来成像生物结构公开(公告)号：US09402593B2
公开(公告)日：2016-08-02
申请号：US13195201
申请日：2011-08-01
Applicant: Yeu-Kuang Hwu , Giorgio Margaritondo , Jung Ho Je
Inventor： Yeu-Kuang Hwu , Giorgio Margaritondo , Jung Ho Je
IPC: A61B6/00
Abstract: Images of blood vessels of a body are obtained by injecting a refraction enhancement contrast agent into the blood vessels to increase a difference in refractive indices of the blood vessels and surrounding material. The blood vessels are irradiated with a penetrating radiation, and an image of the blood vessels is generated based on detected radiation. The image has visible edge enhancement features indicating boundaries of the blood vessels.
Abstract translation: 通过将折射增强造影剂注射到血管中以增加血管和周围材料的折射率差异来获得身体血管的图像。 用穿透性辐射照射血管，并且基于检测到的辐射产生血管的图像。 该图像具有指示血管边界的可见边缘增强特征。
-
公开(公告)号：US09340812B2
公开(公告)日：2016-05-17
申请号：US13971353
申请日：2013-08-20
Applicant: Academia Sinica
Inventor： Chi-Huey Wong , Tsung-I Tsai , Chung-Yi Wu
IPC: C12P19/18
CPC classification number: C12P19/18 , C12P19/04 , C12Y207/0701
Abstract: A novel UDP-Gal regeneration process and its combined use with a galactosyltransferase to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.
Abstract translation: 一种新型的UDP-Gal再生过程及其与半乳糖基转移酶的组合使用，以将半乳糖加入合适的受体底物。 本文还描述了大规模生产Globo系列寡糖的合成方法，其中所述方法可涉及糖基转移酶反应和核苷酸糖再生过程的组合。
-
Patent Agency Ranking
356.发明申请METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE 有权用于治疗泰沙利度胺和病毒性细胞病的方法和组合物公开(公告)号：US20160106728A1
公开(公告)日：2016-04-21
申请号：US14787885
申请日：2014-05-01
Applicant: ACADEMIA SINICA
Inventor： Che-Kun James Shen , Yu-Chi Chou , Tsann-Long Su
IPC: A61K31/473 , A61K9/00
CPC classification number: A61K31/473 , A61K9/0053 , A61K45/06 , C07D221/14 , G01N33/5044 , G01N2333/805 , G01N2800/52 , A61K2300/00
Abstract: Compounds, pharmaceutical compositions, and methods for treating anemia β-thalassemia anemia or sickle cell anemia.
Abstract translation: 化合物，药物组合物和治疗贫血和地贫贫血或镰状细胞性贫血的方法。
-
357.发明授权Robust and low backpressure on-column tunneled frit for nano-UPLC-MS applications 有权用于纳米UPLC-MS应用的坚固和低背压柱上隧道玻璃料公开(公告)号：US09267927B2
公开(公告)日：2016-02-23
申请号：US13112519
申请日：2011-05-20
Applicant: Chao-Jung Chen , Mei-Chun Tseng , Yet-Ran Chen
Inventor： Chao-Jung Chen , Mei-Chun Tseng , Yet-Ran Chen
CPC classification number: G01N30/603 , B01D15/22 , G01N30/6078
Abstract: A durable on-column tunneled frit was developed for use in nanoflow UPLC systems. The frit was tunneled during sol-gel reaction. The tunneled-frit fabrication process is easy and reproducible in terms of back pressure and durability. This design creates low backpressure with high liquid flow, which is suitable for the nanoflowUPLC application. A short packing (2 cm C18 particle) tunneled-frit column was demonstrated to sustain 10,000 psi continuous liquid flow for over one week without any particle leakage or pressure instability. The tunneled-frit was also successfully applied to the fabrication of nanoUPLC trapping and analytical column system. It was demonstrated to have high separation efficiency and sensitivity for the analysis of tryptic peptides as well as improved detection sensitivity for phosphopeptide analysis.
Abstract translation: 开发了一种耐用的柱内隧道玻璃料，用于纳流低压UPLC系统。 玻璃料在溶胶 - 凝胶反应过程中被隧道化。 隧道式玻璃料制造工艺在背压和耐久性方面是容易的和可再现的。 该设计产生低液压，具有高液体流量，适用于纳米FLUP应用。 证明短填料（2cm C18颗粒）隧道玻璃料柱能够持续10,000psi连续液流超过一周，没有任何颗粒泄漏或压力不稳定性。 隧道玻璃料也成功应用于nanoUPLC捕集和分析柱系统的制造。 已被证明具有高分离效率和敏感性，用于分析胰蛋白酶肽，以及提高磷酸肽分析的检测灵敏度。
-
公开(公告)号：US20160046956A1
公开(公告)日：2016-02-18
申请号：US14648053
申请日：2013-11-29
Applicant: Tuan-Hua David Ho , ACADEMIA SINICA
Inventor： Su-May Yu , Shuen-Fang Lo , Liang-Jwu Chen , Tuan-Hua David Ho
CPC classification number: C12N15/8297 , C12N9/0071 , C12N15/8261 , C12N15/8267 , C12N15/8269 , C12N15/8271 , C12N15/8273 , C12Y114/11013 , Y02A40/146
Abstract: The present invention relates to mutant gibberellin 2-oxidase (GA2ox) genes and uses thereof. In particular, the effective mutations disclosed herein can reduce GA2ox enzymatic activity to different extents, leading to various degrees of GA deficient yet beneficial agronomic traits in transgenic plants.
Abstract translation: 本发明涉及突变赤霉素2-氧化酶（GA2ox）基因及其用途。 特别地，本文公开的有效突变可以将GA2ox酶活性降低到不同程度，导致转基因植物中不同程度的GA缺乏但有益的农学性状。
-
359.发明授权Heparin/heparan sulfate-dependent inhibitors of activated protein C and uses thereof in treating hemophilic disorders 有权活化蛋白C的肝素/硫酸乙酰肝素依赖性抑制剂及其在治疗嗜血性疾病中的用途公开(公告)号：US09206246B2
公开(公告)日：2015-12-08
申请号：US14081427
申请日：2013-11-15
Applicant: Academia Sinica
Inventor： Inn-Ho Tsai , An-Chun Cheng
CPC classification number: C07K14/8114 , A61K38/00 , C07K14/463
Abstract: Methods for inhibiting activated protein C (APC) comprising contacting the APC with a Kunitz polypeptide in an amount effective in inhibiting the activity of APC, wherein the Kunitz polypeptide comprises six cysteine residues at positions corresponding to positions 7, 16, 32, 40, 53, and 57 in SEQ ID NO:1, a motif X1GX2CBX′ at positions corresponding to positions 13-18 in SEQ ID NO:1, wherein each of X1 and X2, independently, is any amino acid residue, B is a basic amino acid residue, and X′ is G, A, or V; and at least one heparin-binding motif, which can present at the C-terminus of the Kunitz polypeptide.
Abstract translation: 抑制活化蛋白C（APC）的方法包括以有效抑制APC活性的量使APC与Kunitz多肽接触，其中Kunitz多肽在对应于7,16,32,40,53位的位置包含6个半胱氨酸残基 ，57个，SEQ ID NO：1中的57个，在对应于SEQ ID NO：1中13-18位的位置上的基序X1GX2CBX'，其中X1和X2各自独立地是任何氨基酸残基，B是碱性氨基酸 残基，X'为G，A或V; 和至少一种肝素结合基序，其可以存在于Kunitz多肽的C末端。
-
公开(公告)号：US09190938B2
公开(公告)日：2015-11-17
申请号：US13784068
申请日：2013-03-04
Applicant: ACADEMIA SINICA
Inventor： En-Te Hwu , Ing-Shouh Hwang , Wei-Min Wang
CPC classification number: H02N2/001 , H01L41/0973 , H02N2/0015 , H02N2/0095
Abstract: A piezoelectric actuating device includes a carrier, at least a piezoelectric unit, at least a linked component and a moving component. The piezoelectric unit is disposed on the carrier and includes at least a piezoelectric buzzer. The linked component is disposed corresponding to the piezoelectric unit. One end of the linked component is attached to the piezoelectric buzzer. The moving component is connected with the linked component. When the piezoelectric buzzer is actuated, it can carry the linked component to move correspondingly so as to move the moving component. The piezoelectric actuating device has the advantage of low cost and can achieve the sub-nanometer scale actuating resolution.
Abstract translation: 压电致动装置包括载体，至少压电单元，至少一个连接部件和移动部件。 压电单元设置在载体上并且至少包括压电蜂鸣器。 连接部件对应于压电单元设置。 连接部件的一端连接到压电蜂鸣器。 移动组件与链接组件连接。 当压电蜂鸣器被致动时，它可以携带相连的部件相应地移动以移动移动部件。 压电驱动装置具有成本低廉的优点，可实现亚纳米级的致动分辨率。
-
-
-
-
-
-
-
-
-
Search Results
1251
records
(took 0.167 seconds)
